 |
114 Diseases |  |
361 Trials |
|
361 Trials |  |
7200 News |  |
| «12...1213141516171819202122...100101» |
- | Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Journal: Optimisation of Solid-Phase Extraction and LC-MS/MS Analysis of Six Breast Cancer Drugs in Patient Plasma Samples. (Pubmed Central) - Oct 28, 2023
14.3%) and accuracy (inter-day bias -12.7-13.5%). Finally, its applicability was successfully proven by the analysis of samples from breast cancer patients.
- ||| Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Journal, Adverse events: Hematological Events Potentially Associated with CDK4/6 Inhibitors: An Analysis from the European Spontaneous Adverse Event Reporting System. (Pubmed Central) - Oct 28, 2023
Abemaciclib and palbociclib were often combined with fulvestrant, while ribociclib was generally associated with letrozole. Pharmacovigilance studies are crucial for the early identification of potential ADRs and to better differentiate the toxicity profile of the different CDK4/6 inhibitors, particularly in a real-world setting.
- | ketoconazole / Generic mfg., letrozole / Generic mfg., erlotinib / Generic mfg.
Journal: New 1,2,3-Triazole/1,2,4-triazole Hybrids as Aromatase Inhibitors: Design, Synthesis, and Apoptotic Antiproliferative Activity. (Pubmed Central) - Oct 28, 2023
Pharmacovigilance studies are crucial for the early identification of potential ADRs and to better differentiate the toxicity profile of the different CDK4/6 inhibitors, particularly in a real-world setting. The antiproliferative activity of the new hybrids against four cancer cells was studied using Erlotinib as a control...Results revealed that compounds 6a and 6b were the most potent aromatase inhibitors, with IC50 values of 0.12
- | Ibrance (palbociclib) / Pfizer
Preclinical, Journal: In Vitro microRNA Expression Profile Alterations under CDK4/6 Therapy in Breast Cancer. (Pubmed Central) - Oct 28, 2023
Because they are secreted and significantly upregulated in the microenvironment of tumor cells, miRs-100, -10b and -182 are promising circulating biomarkers that can be used to predict or detect therapy responses under CDK inhibition. MiR-10a, miR-15b, miR-21, miR-23a and miR-23c are potential tissue-based biomarkers.
- | letrozole / Generic mfg.
Journal: Letrozole-stimulated endometrial preparation protocol is a superior alternative to hormone replacement treatment for frozen embryo transfer in women with polycystic ovary syndrome, a cohort study. (Pubmed Central) - Oct 28, 2023
LS protocol is suitable for all types of patients with PCOS. LS should be considered the preferred endometrial preparation protocol for women with PCOS.
- || Orserdu (elacestrant) / Menarini
Review, Journal, Metastases: Elacestrant for ER-Positive HER2-Negative Advanced Breast Cancer. (Pubmed Central) - Oct 27, 2023
Phase 1 and 3 trials showed elacestrant was safe and improved progression-free survival in patients with endocrine receptor 1 (ESR1) mutations who failed cyclin-dependent kinase 4/6 inhibitor (CDK 4/6i) plus 1 prior endocrine therapy compared with standard of care (SOC) (fulvestrant, anastrozole, letrozole, or exemestane monotherapy). Elacestrant is currently being studied in CDK 4/6 inhibitor na
- || Ibrance (palbociclib) / Pfizer, Tukysa (tucatinib) / Pfizer
Trial completion, Trial completion date, Combination therapy, Metastases: Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer (clinicaltrials.gov) - Oct 27, 2023
P1/2, N=42, Completed, Sponsor: University of Colorado, Denver
Elacestrant is currently being studied in CDK 4/6 inhibitor na Active, not recruiting --> Completed | Trial completion date: Mar 2024 --> Feb 2023
- | Ibrance (palbociclib) / Pfizer
Journal, Metastases: Overall survival in Japanese patients with ER+/HER2- advanced breast cancer treated with first-line palbociclib plus letrozole. (Pubmed Central) - Oct 26, 2023
P=N/A
Active, not recruiting --> Completed | Trial completion date: Mar 2024 --> Feb 2023 In this population of Japanese women with ER+/HER2- ABC, median OS was over 7
- | letrozole / Generic mfg., capecitabine / Generic mfg.
Journal: Late recurrence of lobular breast carcinoma presented as gastric metastasis. (Pubmed Central) - Oct 26, 2023
The sample showed infiltration by lobular breast carcinoma CK7 (+), CK20 (-), CDX2 (-), GATA3 (+) GCDFP15 (+) RE (+) RP (-) HER2 (-). Treatment with capecitabine was started, with which it continues currently.
- | Ibrance (palbociclib) / Pfizer, Keytruda (pembrolizumab) / Merck (MSD)
Enrollment closed: Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer (clinicaltrials.gov) - Oct 26, 2023
P2, N=40, Active, not recruiting, Sponsor: City of Hope Medical Center
Treatment with capecitabine was started, with which it continues currently. Suspended --> Active, not recruiting
- || Fyarro (nanoparticle albumin-bound rapamycin) / Aadi Biosci
Enrollment open, Combination therapy, Metastases: Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer (clinicaltrials.gov) - Oct 26, 2023
P2, N=29, Recruiting, Sponsor: Aadi Bioscience, Inc.
Suspended --> Active, not recruiting Not yet recruiting --> Recruiting
- | letrozole / Generic mfg.
Trial completion date, Trial primary completion date, Combination therapy: Study of Letrozole in Recurrent Gliomas (clinicaltrials.gov) - Oct 25, 2023
P1, N=42, Active, not recruiting, Sponsor: University of Cincinnati
Not yet recruiting --> Recruiting Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Sep 2023 --> Sep 2024
- | letrozole / Generic mfg.
Journal: Production of sterile mono-sex triploid yellow drum (Nibea albiflora): genotypic females and sex-reversed phenotypic males with emphasis on utilization as surrogate broodstock. (Pubmed Central) - Oct 25, 2023
Then, the mono-male triploids were produced by the sex reversal of mono-female triploids with oral administration of letrozole (LZ)...In addition, high dmrt1 expression levels confirmed the masculinization and testicular development of sex-reversed triploid males by LZ. Our findings provide an efficient protocol to produce sterile mono-sex triploid yellow drum and provide new insights into the mechanism of gonadal sterility of triploid fish.
- | Ibrance (palbociclib) / Pfizer
Journal, Metastases: Efficacy of Limited Dose Modifications for Palbociclib-Related Grade 3 Neutropenia in Hormone Receptor-Positive Metastatic Breast Cancer. (Pubmed Central) - Oct 23, 2023
Our findings provide an efficient protocol to produce sterile mono-sex triploid yellow drum and provide new insights into the mechanism of gonadal sterility of triploid fish. Limited dose modification for palbociclib-related grade 3 neutropenia may lead to longer PFS, without increasing toxicity, than the conventional dose scheme.
- || Mifeprex (mifepristone) / Danco Laboratories
Clinical, Journal: Cocktail treatment by GnRH-antagonist, letrozole, and mifepristone for the prevention of ovarian hyperstimulation syndrome: a prospective randomized trial. (Pubmed Central) - Oct 22, 2023
There was no significant difference in cumulative live birth rates (LBRs) between the combination and mifepristone group (74.4% vs. 76.9%). The combination treatment effectively reduces the incidence of moderate/severe OHSS in high-risk women.
- | Ibrance (palbociclib) / Pfizer
Journal: Concomitant Use of Proton Pump Inhibitors and Palbociclib Among Patients With Breast Cancer. (Pubmed Central) - Oct 22, 2023
Both clinical PFS and OS in the concomitant PPI group were consistently poor in patients receiving endocrine-sensitive and endocrine-resistant treatment. These findings suggest that concomitant use of PPIs with palbociclib may hinder the complete therapeutic benefits of palbociclib in patients with breast cancer.
- | Journal, Metastases: Ribociclib-induced visual hallucination in a patient with metastatic breast cancer. (Pubmed Central) - Oct 22, 2023
These findings suggest that concomitant use of PPIs with palbociclib may hinder the complete therapeutic benefits of palbociclib in patients with breast cancer. To our knowledge, this is the first reported case of hallucinations caused by ribociclib; notably, it shows that symptoms may develop in the early stage of treatment.
- | letrozole / Generic mfg.
Journal: Laparoscopic oocyte retrieval for fertility preservation in a patient with squamous cell carcinoma of the vagina. (Pubmed Central) - Oct 22, 2023
Letrozole is a valuable strategy to reduce high estrogen in patients with gynecological cancer undergoing controlled ovarian stimulation. Laparoscopy oocyte retrieval, performed under regional anesthesia, can be performed in an ambulatory setting and should be considered an effective fertility preservation strategy in patients with large vaginal tumors.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, letrozole / Generic mfg., Kisqali (ribociclib) / Novartis
Journal, Metastases: Toxic hepatitis in metastatic breast cancer patient using ribociclib and denosumab. (Pubmed Central) - Oct 22, 2023
Since the liver biopsy was toxic hepatitis, it was thought that other drugs used by the patient might cause this toxicity, and a significant decrease was observed in liver values after discontinuation of denosumab. Denosumab-induced liver toxicity is very rare, and there are only a limited number of cases in the literature.
- || Piqray (alpelisib) / Novartis, Kisqali (ribociclib) / Novartis
Trial completion date, Trial primary completion date, Metastases: CLEE011X2107: Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer (clinicaltrials.gov) - Oct 17, 2023
P1/2, N=255, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Denosumab-induced liver toxicity is very rare, and there are only a limited number of cases in the literature. Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Nov 2023 --> Nov 2024
- ||| atirmociclib (PF-07220060) / Pfizer, tagtociclib (PF-07104091) / Pfizer
Enrollment change, Combination therapy, Metastases: C4391002: A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors (clinicaltrials.gov) - Oct 17, 2023
P1b/2, N=240, Recruiting, Sponsor: Pfizer
Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Nov 2023 --> Nov 2024 N=144 --> 240
- | Mifeprex (mifepristone) / Danco Laboratories
Enrollment open, Trial completion date, Trial primary completion date, Head-to-Head: The Use of Letrozole or Mifepristone for Pretreatment of Medical Termination of Pregnancy (clinicaltrials.gov) - Oct 17, 2023
P4, N=144, Recruiting, Sponsor: KK Women's and Children's Hospital
N=144 --> 240 Not yet recruiting --> Recruiting | Trial completion date: Nov 2023 --> Nov 2024 | Trial primary completion date: Aug 2023 --> Aug 2024
- ||||| Kisqali (ribociclib) / Novartis
Trial initiation date, Trial primary completion date, Real-world evidence: ADJUVANT WIDER: Phase IIIb Study of Ribociclib + ET in Early Breast Cancer (clinicaltrials.gov) - Oct 16, 2023
P3, N=2500, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting | Trial completion date: Nov 2023 --> Nov 2024 | Trial primary completion date: Aug 2023 --> Aug 2024 Initiation date: Sep 2023 --> Jan 2024 | Trial primary completion date: Jun 2030 --> Jul 2028
- |||||| Ibrance (palbociclib) / Pfizer
New trial, Combination therapy, Metastases: Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself. (clinicaltrials.gov) - Oct 16, 2023
P=N/A, N=782, Active, not recruiting, Sponsor: Pfizer
- |||||| camizestrant (AZD9833) / AstraZeneca
Enrollment open: An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) (clinicaltrials.gov) - Oct 16, 2023
P3, N=5500, Recruiting, Sponsor: AstraZeneca
Initiation date: Sep 2023 --> Jan 2024 | Trial primary completion date: Jun 2030 --> Jul 2028 Not yet recruiting --> Recruiting
- || AiTan (rivoceranib) / HLB Bio Group
P2 data, Journal, Metastases: Phase II study of apatinib plus exemestane in estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer. (Pubmed Central) - Oct 13, 2023
Apatinib plus exemestane exhibited objective efficacy in patients with ER+/HER2- MBC who have failed multiple lines of treatment. The AEs of apatinib required close monitoring and most of patients were well tolerated.
- | letrozole / Generic mfg.
Preclinical, Journal: Comprehensive Analysis of Gut Microbiota Alteration in the Patients and Animal Models with Polycystic Ovary Syndrome. (Pubmed Central) - Oct 12, 2023
The clinical patients and letrozole-induced animal models were determined on PCOS indexes and gut microbiota, and fecal microbiota transplantation (FMT) was conducted...Overall, the results indicate the involvement of gut microbiota in PCOS and its possible alleviation of endocrinal and reproductive dysfunctions through several special bacteria taxa, which can function as the biomarker or potential target for diagnosis and treatment. These results can provide the new insights for treatment and prevention strategies of PCOS.
- | Verzenio (abemaciclib) / Eli Lilly
Trial completion date: A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread (clinicaltrials.gov) - Oct 12, 2023
P1b, N=198, Active, not recruiting, Sponsor: Eli Lilly and Company
These results can provide the new insights for treatment and prevention strategies of PCOS. Trial completion date: Sep 2023 --> Dec 2024
- | letrozole / Generic mfg.
Trial completion date, Trial primary completion date: NCI-2021-12428: Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer (clinicaltrials.gov) - Oct 11, 2023
P4, N=60, Suspended, Sponsor: University of Washington
Trial completion date: Sep 2023 --> Dec 2024 Trial completion date: Sep 2023 --> Dec 2023 | Trial primary completion date: Sep 2023 --> Dec 2023
- | letrozole / Generic mfg., everolimus / Generic mfg.
Trial completion date, Trial primary completion date, Metastases: Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer (clinicaltrials.gov) - Oct 10, 2023
P2, N=42, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Sep 2023 --> Dec 2023 | Trial primary completion date: Sep 2023 --> Dec 2023 Trial completion date: Apr 2023 --> Apr 2028 | Trial primary completion date: Apr 2022 --> Apr 2028
- ||| Verzenio (abemaciclib) / Eli Lilly
Trial completion date: MONARCH 3: A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer (clinicaltrials.gov) - Oct 10, 2023
P3, N=493, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Apr 2023 --> Apr 2028 | Trial primary completion date: Apr 2022 --> Apr 2028 Trial completion date: Sep 2024 --> Dec 2024
- | letrozole / Generic mfg.
Journal: NLRP3 Inflammasome-dependent Pathway is Involved in the Pathogenesis of Polycystic Ovary Syndrome. (Pubmed Central) - Oct 10, 2023
Ovarian specimens were collected from mice with polycystic ovarian changes induced by a high-fat diet and letrozole...The RT-qPCR results revealed that the expression levels of GANAB, ALG-5, HSD3B2, ULK1, PTK2B, and Casp7 in KGN cells after NLRP3 overexpression were significantly higher than those in control cells, which was consistent with the RNA-Seq results. Taken together, the NLRP3 inflammasome-dependent pathway is involved in the pathogenesis of PCOS not only by mediating pyroptosis, but also by regulating glycan synthesis, sex hormone synthesis, autophagy, and apoptosis in GCs.
- | clomifene citrate / Generic mfg.
Preclinical, Journal, Metabolomic study: Exploring the mechanism of clomiphene citrate to improve ovulation disorder in PCOS rats based on follicular fluid metabolomics. (Pubmed Central) - Oct 10, 2023
Kyoto Encyclopedia of Genes and Genomes pathway enrichment also showed that the CC group mainly engaged in tryptophan metabolism and steroid hormone biosynthesis. CC can improve ovulation disorders in rats, and its mechanism is related to the regulation of the secretion of serum hormone and follicular fluid metabolites and the amelioration of multi-metabolic pathways.
- | Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, Herceptin (trastuzumab) / Roche
Enrollment open, Trial initiation date: ARIADNE: Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer (clinicaltrials.gov) - Oct 10, 2023
P2, N=370, Recruiting, Sponsor: Karolinska University Hospital
CC can improve ovulation disorders in rats, and its mechanism is related to the regulation of the secretion of serum hormone and follicular fluid metabolites and the amelioration of multi-metabolic pathways. Not yet recruiting --> Recruiting | Initiation date: Jun 2023 --> Oct 2023
- |||||||||| defactinib (VS-6063) / Verastem, avutometinib (VS-6766) / Verastem
New P3 trial: RAMP 301: A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer (clinicaltrials.gov) - Oct 9, 2023
P3, N=270, Not yet recruiting, Sponsor: Verastem, Inc.
- | Orserdu (elacestrant) / Menarini
New P2 trial: RECAST-DCIS: DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment (clinicaltrials.gov) - Oct 9, 2023
P2, N=300, Not yet recruiting, Sponsor: QuantumLeap Healthcare Collaborative
- vepdegestrant (ARV-471) / Arvinas, Pfizer
Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3 (Exhibition area) - Oct 6, 2023 - Abstract #ESMOAsia2023ESMO_Asia_655;
P1, P1/2,
In the phase 3 portion, pts (N?1130) will be randomized to vepdegestrant + palbociclib or letrozole + palbociclib. The primary endpoint is PFS by BICR.
- letrozole / Generic mfg., capecitabine / Generic mfg.
Combination of chemotherapy with endocrinal therapy as upfront treatment of metastatic breast cancer in hormone receptor- positive, HER2 -negative disease: A phase II randomised clinical trial (Exhibition area) - Oct 6, 2023 - Abstract #ESMOAsia2023ESMO_Asia_644;
P2
Anaemia (28.3%) and hand & foot syndrome (43.8%) were significantly more common in the capecitabine/letrozole arm. Conclusions Capecitabine combined with letrozole have showed a trend towards improvement in progression free survival with potential more benefit to certain sub-groups and the combination showed acceptable safety profile consistent with the established known safety profile of both letrozole and capecitabine.
- | Kisqali (ribociclib) / Novartis
Enrollment open, Metastases: Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer (clinicaltrials.gov) - Oct 5, 2023
P2, N=202, Recruiting, Sponsor: Korea University Guro Hospital
Conclusions Capecitabine combined with letrozole have showed a trend towards improvement in progression free survival with potential more benefit to certain sub-groups and the combination showed acceptable safety profile consistent with the established known safety profile of both letrozole and capecitabine. Not yet recruiting --> Recruiting
- ||| Verzenio (abemaciclib) / Eli Lilly
Enrollment open: TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer (clinicaltrials.gov) - Oct 5, 2023
P2, N=90, Recruiting, Sponsor: Dana-Farber Cancer Institute
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Ibrance (palbociclib) / Pfizer
Trial primary completion date, Liquid biopsy, Metastases, Biopsy: ICRG0201: Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies. (clinicaltrials.gov) - Oct 3, 2023
P2, N=80, Recruiting, Sponsor: International Cancer Research Group, United Arab Emirates
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2023 --> Jan 2024
- ||| AVZO-021 / Avenzo Therap
Enrollment open: ARTS-021-1001: Study of AVZO-021 in Patients with Advanced Solid Tumors (clinicaltrials.gov) - Sep 30, 2023
P1/2, N=192, Recruiting, Sponsor: Allorion Therapeutics Inc
Trial primary completion date: Jun 2023 --> Jan 2024 Not yet recruiting --> Recruiting
- ||| BPI-1178 / Beta Pharma
Enrollment change, Trial primary completion date, Combination therapy, Metastases: A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer (clinicaltrials.gov) - Sep 28, 2023
P1/2, N=224, Recruiting, Sponsor: Beta Pharma (Suzhou) Co., Ltd.
Not yet recruiting --> Recruiting N=122 --> 224 | Trial primary completion date: Jun 2023 --> Mar 2024
- | fulvestrant / Generic mfg.
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study (clinicaltrials.gov) - Sep 28, 2023
P2, N=4, Completed, Sponsor: M.D. Anderson Cancer Center
N=122 --> 224 | Trial primary completion date: Jun 2023 --> Mar 2024 Recruiting --> Completed | N=124 --> 4 | Trial completion date: Apr 2024 --> Sep 2023 | Trial primary completion date: Apr 2024 --> Sep 2023
- || lerociclib (G1T38) / Walvax, Pepper Bio
Enrollment change, Trial withdrawal, Combination therapy, Metastases: Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer (clinicaltrials.gov) - Sep 28, 2023
P3, N=0, Withdrawn, Sponsor: EQRx International, Inc.
Recruiting --> Completed | N=124 --> 4 | Trial completion date: Apr 2024 --> Sep 2023 | Trial primary completion date: Apr 2024 --> Sep 2023 N=320 --> 0 | Active, not recruiting --> Withdrawn
- Tecentriq (atezolizumab) / Roche, Reolysin (pelareorep) / Oncolytics, Andrus Reo
Analysis of the HR+/HER2- breast cancer tumor microenvironment following immune priming with pelareorep and atezolizumab using imaging mass cytometry (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_927;
Conclusions In accordance with the prior AWARE-1 results, IMC demonstrated an enhanced immune state of the tumors after treatment. IMC allows us to analyze the potent immune response and cellular interactions in the TME and characterization of these complex interactions provides a better understanding of the key mechanisms of action of these treatments in order to plan future clinical trials.
- || letrozole / Generic mfg., clomifene citrate / Generic mfg.
Preclinical, Review, Journal: In vitro fertilisation for unexplained subfertility. (Pubmed Central) - Sep 27, 2023
IVF may improve LBR over unstimulated IUI. Data should be interpreted with caution as overall evidence quality was low.
- letrozole / Generic mfg.
Efficiency and safety of ovarian stimulation with letrozole and levonorgestrel-intrauterine system after combined fertility-sparing treatment of women with atypical endometrial lesions (Room 1121) - Sep 25, 2023 - Abstract #ESGE2023ESGE_328;
- || tamoxifen / Generic mfg.
Retrospective data, Review, Journal: The effectiveness of controlled ovarian stimulation with tamoxifen for patients with estrogen-sensitive breast cancer: A systematic review and meta-analysis. (Pubmed Central) - Sep 25, 2023
Statistically significant decrease was observed in PEL during COS with letrozole compared with tamoxifen (95% CI, [1414.4, 4953.7]). The quality did not differ between COS with tamoxifen and COS with letrozole or gonadotropin only.
- | Herceptin (trastuzumab) / Roche
Preclinical, Journal: Efficacy of copper nanoparticles encapsulated in soya lecithin liposomes in treating breast cancer cells (MCF-7) in vitro. (Pubmed Central) - Sep 25, 2023
There are several drugs approved by FDA used in breast cancer treatment like Cyclophosphamide, Doxorubicin Hydrochloride, Femara, Herceptin, etc. Each has several side effects as well as treatment, which limits the use of drugs due to heart failure, pulmonary dysfunction, or immunodeficiency...Some drugs have been approved for use in cancer treatment under the concept of drug delivery, such as Doxil (liposomal loaded doxorubicin)...The cytotoxicity assay showed that the IC of Cu/SLP is smaller than that of free CuNPs. These results give clear evidence of the efficacy of using the combined Cu/SLP rather than CuNPs alone as a model drug carrier prepared from plant origin against cancer, both medically and economically.